focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,783.50
Bid: 1,780.00
Ask: 1,780.50
Change: -29.00 (-1.60%)
Spread: 0.50 (0.028%)
Open: 1,792.50
High: 1,802.00
Low: 1,775.50
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks Down As Clinton Remarks Hit Pharma Sector

Thu, 25th Aug 2016 11:00

LONDON (Alliance News) - Pharmaceutical stocks dragged the FTSE 100 lower midday Thursday, after the sector was hit by comments made by presidential nominee Hillary Clinton, who raised concerns about the price increase of an allergy product by US pharmaceutical company Mylan.

The price of the company's EpiPen product has risen by 480% since the company acquired it in 2007, moving from USD100 for a 2-pack in 2007 to its current cost of around USD600.

"That's outrageous - and it's just the latest troubling example of a company taking advantage of its consumers," said Clinton in a statement published on her Facebook profile. "It's wrong when drug companies put profits ahead of patients, raising prices without justifying the value behind them."

Mike van Dulken, head of research at Accendo Markets, said Clinton's comments will cause concern for healthcare groups and their investors everywhere.

"As always, the industry remains between a rock and a hard place, treading the fine line between balancing the costs of clinical success (and failure) with the economic laws of supply and demand, all the while trying (often in vain) to satisfy demanding stakeholders without appearing to view the sick as merely a commercial opportunity," van Dulken said.

Hikma Pharmaceuticals was down 3.6%, Shire down 4.4%, AstraZeneca down 1.8%, and GlaxoSmithKline down 0.7%.

The FTSE 100 was down 0.3%, or 18.32 points, at 6,817.46. The FTSE 250 was down 0.8% at 17,869.99 and the AIM All-Share was down 0.5% at 788.35.

In Europe, the French CAC 40 was down 0.7% and the German DAX 30 was down 0.9%

Futures indicated a lower open for Wall Street, with the DJIA, S&P 500, and Nasdaq 100 all pointed down 0.1%.

Elsewhere on the London market, CRH was the best performer in the blue-chip index, up 3.4%. The Irish building materials company said its profit came in six times higher than a year earlier in its first half, reflecting continued positive momentum in the Americas and the inclusion of acquisitions made in the second half of 2015.

CRH said trading conditions in the first half in Europe reflected the modest impact of early-stage economic recovery.

In the Americas, the company said it expects the positive momentum seen in construction markets during the first half of the year to continue into the second, while in Asia the positive demand backdrop experienced in the Philippines looks set to continue for the rest of the year.

ITV said it has withdrawn its proposal to acquire Entertainment One, after the television and film producer rejected the bid earlier this month.

ITV made an offer for Entertainment One at 236.00 pence per share, valuing it at around GBP1.03 billion, in early August, but this bid was rebuffed by Entertainment One's board as it said it "fundamentally undervalues" the business.

ITV said Thursday that it has a "clear view of the value" of Entertainment One, and it "appears this value is different to the level at which the board of eOne would currently engage in a more formal process."

The broadcaster said it has a "clear strategy to build a stronger, more diversified international business and will continue its disciplined approach to evaluating its healthy pipeline of potential investment opportunities."

ITV traded up 1.5%, while Entertainment One was the biggest faller in the FTSE 250 index, down 12% to 220.21p.

Infrastructure investor John Laing Group said its net asset value rose in the first half of 2016 and maintained its full year guidance for investment commitments.

The company's net asset value per share also rose to 263.00 pence at the end of its first half from 242.00p at the end of December and 224.00p a year earlier.

"These results demonstrate that our business model is delivering consistent results, and has the ability to cope with today's changing macro-economic environment, including the impact of Brexit," said Chief Executive Olivier Brousse.

The stock was one of the best FTSE 250 performers, up 5.6%.

Playtech was up 4.3% after the gaming technology company reported growth in revenue in the first half and declared a special dividend, but said its profit dipped due to higher finance costs hit by the depreciation of sterling.

Playtech added it was "cognisant" of the need for an efficient balance sheet and said its currently high cash balance is complemented by cash from operations.

It added it is able to return cash to shareholders without impact in its outlook on making more acquisitions. As such, it will pay an interim dividend of 11.0 euro cents per share, up 15% from the previous year, and declared a special dividend of a further 46.0 cents per share.

Still ahead in the economic calendar, US initial and continuing jobless claims are at 1330 BST, alongside durable goods data. Markit's US services and composite PMI readings are at 1445 BST.

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.